SCHEMBL1236746

SCHEMBL1236746

COCCN(CCCc1nc(C)no1)c1cc(C)nc2c(-c3ccc(OC)cc3OC)c(C)nn12

nearest known ligand 0.77

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 19/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1236480 0.93 CRHR1 (0.80) CRHR1
SCHEMBL5872522 0.84 CRHR1 (1.00) CRHR1
SCHEMBL5445010 0.83 CRHR1 (0.91) CRHR1
SCHEMBL1236372 0.83 CRHR1 (0.68) CRHR1
SCHEMBL12019825 0.82 CRHR1 (0.80) CRHR1
SCHEMBL2810382 0.79 CRHR1 (0.83) CRHR1
SCHEMBL12889089 0.79 CRHR1 (0.81) CRHR1
SCHEMBL14491028 0.77 CRHR1 (0.86) CRHR1
SCHEMBL5447883 0.77 CRHR1 (0.86) CRHR1
SCHEMBL1237264 0.77 CRHR1 (1.00) CRHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080194589-A1 Pyrazolo[1,5-Alpha]Pyrimidinyl Derivatives Useful as Corticotropin-Releasing Factor (Crf) Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-08-14 US claimed
EP-1802627-A1 PYRAZOLO (1,5-ALPHA) PYRIMIDINYL DERIVATIVES USEFUL AS CORTICOTROPIN-RELEASING FACTOR (CRF) RECEPTOR ANTAGONISTS SB Pharmco Puerto Rico Inc. (PR) 2007-07-04 EP claimed
WO-2006044958-A1 PYRAZOLO [1,5-ALPHA] PYRIMIDINYL DERIVATIVES USEFUL AS CORTICOTROPIN-RELEASING FACTOR (CRF) RECEPTOR ANTAGONISTS SB PHARMCO PUERTO RICO INC. (PR) 2006-04-27 WO claimed
WO-2019075394-A1 COMPOUNDS FOR TREATMENT OF EMOTIONAL/PSYCHOLOGICAL SYMPTOMS IN FRAGILE X SYNDROME VANDERKLISH PETER (US) 2019-04-18 WO disclosed
EP-1802627-B1 PYRAZOLO (1,5-ALPHA) PYRIMIDINYL DERIVATIVES USEFUL AS CORTICOTROPIN-RELEASING FACTOR (CRF) RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORK LTD (IE) 2012-08-29 EP disclosed
US-7879862-B2 Central nervous system disorders; psychological disorders; anxiolytic agents; irritable bowel syndrome; antidepressants SMITHKLINE BEECHAM (CORK) LIMITED (IE) 2011-02-01 US disclosed
US-7879862-B2 Central nervous system disorders; psychological disorders; anxiolytic agents; irritable bowel syndrome; antidepressants SMITHKLINE BEECHAM (CORK) LIMITED (IE) 2011-02-01 US disclosed
US-7879862-B2 Central nervous system disorders; psychological disorders; anxiolytic agents; irritable bowel syndrome; antidepressants SMITHKLINE BEECHAM (CORK) LIMITED (IE) 2011-02-01 US disclosed
US-20080194589-A1 Pyrazolo[1,5-Alpha]Pyrimidinyl Derivatives Useful as Corticotropin-Releasing Factor (Crf) Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-08-14 US disclosed
US-20080194589-A1 Pyrazolo[1,5-Alpha]Pyrimidinyl Derivatives Useful as Corticotropin-Releasing Factor (Crf) Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-08-14 US disclosed
US-20080194589-A1 Pyrazolo[1,5-Alpha]Pyrimidinyl Derivatives Useful as Corticotropin-Releasing Factor (Crf) Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-08-14 US disclosed
EP-1802627-A1 PYRAZOLO (1,5-ALPHA) PYRIMIDINYL DERIVATIVES USEFUL AS CORTICOTROPIN-RELEASING FACTOR (CRF) RECEPTOR ANTAGONISTS SB Pharmco Puerto Rico Inc. (PR) 2007-07-04 EP disclosed
WO-2006044958-A1 PYRAZOLO [1,5-ALPHA] PYRIMIDINYL DERIVATIVES USEFUL AS CORTICOTROPIN-RELEASING FACTOR (CRF) RECEPTOR ANTAGONISTS SB PHARMCO PUERTO RICO INC. (PR) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194589-A1 Pyrazolo[1,5-Alpha]Pyrimidinyl Derivatives Useful as Corticotropin-Releasing Factor (Crf) Receptor Antagonists CRHR1, CRH, CRHR2 CRHR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.